Ezra has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its new artificial intelligence (AI) technology, Ezra Flash, for use in brain imaging.

Ezra Flash is designed to improve the quality of magnetic resonance imaging (MRI).

The new AI technology will allow the company to launch the 30-minute full-body MRI scan, which is claimed to be the first of its kind across the world.

A rapid MRI protocol that was developed by the company generates noisy images. Ezra Flash can address this issue by improving the quality of these images.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ezra founder and CEO Emi Gal said: “Our mission at Ezra is to detect cancer early for everyone in the world and I’m really excited about this new AI enabling us to make our scan more affordable.

“By boosting quality while reducing scan time, we’re decreasing our cost for a full body MRI by 30% and we’re passing these cost savings to our customers.”

The Ezra Flash AI underwent training by leveraging the company’s longitudinal MRI dataset, encompassing a vast collection of MRI images obtained from both healthy individuals and patients.

Ezra trained the AI to identify the crucial components of an MRI scan that are required for producing a complete and precise image.

The latest FDA clearance marks a significant milestone for Ezra as it becomes the first global company to deploy AI across imaging, analysis and reporting aspects of the cancer screening process.

The company’s Ezra Prostate AI enables radiologists to analyse MR images of the prostate.

It also offers Ezra Reporter AI that generates an easy-to-understand radiology report, which can be used by medical professionals to share screening results with individuals.